Management Policies

Message from Leadership

Performance recovered in the second quarter, but first-half sales and profits were down due to the impact of extraordinary factors.

Net sales fell year on year, affected by lower sales in Japan and China, but sales increased in all other regions.

Operating profit declined, owing to the impact of extraordinary factors and an increase in selling, general and administrative (SG&A) expenses.

Nov. 2025

Kaoru Asano
President

In the first six months of the fiscal year ending March 31, 2026, sales and profits were down year on year. Despite a recovery in the second quarter, performance was affected by extraordinary factors. These include the implementation of order restrictions in the first quarter accompanying a core system transition in Japan, as well as inventory revaluations on overseas inventories. In addition, Sysmex felt the effects of yen appreciation and a changing market environment in China. As a result, net sales declined 4.1% year on year, operating profit was down 25.9%, and profit attributable to owners of the parent fell 26.9%.

Looking at performance by destination, regent sales rose in each field in the Americas, EMEA, and AP regions. In the Americas, sales of instrument and reagent sales were robust in the hematology*¹ and urinalysis fields, and sales of Amyloid-β*² reagents contributed substantially. In the EMEA region, sales were affected somewhat by geopolitical factors in the Middle East, but sales of instruments and reagents remained solid, particularly in key countries. In Germany, we secured large tenders, including for the CN™-Series, and further growth is expected going forward. In the Asia Pacific region, hematology reagent sales in India grew significantly, and in Southeast Asian countries such as the Philippines, both the hematology and urinalysis fields expanded steadily, resulting in double-digit sales growth.

In the medical robotics business, the number of surgeries is steadily increasing in both Japan and countries such as Singapore and Malaysia. We anticipate further market expansion, as we expect to receive regulatory approval in Europe.

We have revised downward our consolidated financial forecast for the fiscal year ending March 31, 2026, owing to a changing operating environment in China. We now anticipate net sales of ¥510.0 billion and operating profit of ¥76.0 billion. As initially forecast, we expect to pay dividends for the year of ¥38 per share (comprising interim and year-end dividends of ¥19 each). This represents a year-on-year increase of ¥6, including a commemorative dividend.

Looking ahead to the fiscal year ending March 31, 2027, we aim to increase both sales and profits by driving growth through the expansion of our hemostasis business in Europe and the United States, continued growth in emerging markets such as India, the launch of our clinical chemistry business, and recovery in Japan and China.

We would like to ask our stakeholders for their continued support and understanding of our endeavors.

■Financial Forecast for the Fiscal Year ending March 31, 2026 (billions of yen)

	Net Sales	Operating profit	Profit attributable to owners of the parent
Announced November 2025	5,100	760	450
Announced May 2025	5,350	915	570
[Reference] Fiscal year ended March 31, 2025	5,086	915	536

■Assumed Full Year Exchange Rates for Fiscal Year ending March 31, 2025 (JPY)

	1USD	1EUR	1CNY
Announced November 2025	148.5	171.5	20.8
Announced May 2025	142.0	160.0	19.5
[Reference] Fiscal year ended March 31, 2025	152.6	163.8	21.1

*1: Hematology field: The field of in vitro diagnostics that determines whether precise testing is necessary by analyzing the number, type and size of red, white and other blood cells.

*2: Amyloid-β: A key constituent of senile plaque, a pathological characteristic of the brain tissue of patients with Alzheimer’s diseases, composed of around 40 amino acids.

Back to "Management Policies"